Anal Carcinoma Clinical Trial
Official title:
Malignant Progression of Anal Intra-epithelial Neoplasia in a Cohort of Patients
Evaluation of the 3-years anal carcinoma (AC) incidence in patient with anal AIN3 lesions, and factors associated with this AC. A retrospective cohort study will be conducted (2000-2013) followed by a prospective cohort study (starting in 2013) with new diagnoses of anal AIN3 lesion. The main outcome is histology proven AC. The 3-years incidence rate of AC will be calculated. Factors associated with AC will be estimated using a multivariate Cox regression model.
"Background : Incidence of anal carcinoma (AC) is considerably increasing, but no data on
risk of AC in patient with anal AIN3 lesions are available, nor french recommendations about
screening and treatment of anal AIN3 lesions.
Objective : Evaluation of the AC incidence in patient with anal AIN3 lesions, and factors
associated with this AC.
Population : Patients with a diagnosis of anal AIN3 lesion will be included and followed for
3 years. Patients with past history of AC won't be included.
Study design : Retrospective cohort study will be conducted from 2000 using diagnostic codes
of anal AIN3 lesion in histo-pathology departments. Then a prospective cohort study will be
conducted with new diagnoses of anal AIN3 lesion.
Outcome : The main outcome is histology proven AC. AC identification can be done either by
using diagnostic codes of AC in histo-pathology departments (for retrospective cases), or
prospectively.
Statistics : The incidence rate of AC will be calculated. Factors associated with AC will be
estimated using a multivariate Cox regression model.
Number of patients : 1000 Number of centers : 35 Length of follow-up: 3 years at least
Length of study : 3 years of inclusion and 3 years of follow-up at least"
;
Observational Model: Cohort
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02408861 -
Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
|
Phase 1 | |
Recruiting |
NCT05663502 -
Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers
|
||
Active, not recruiting |
NCT00867464 -
Extended Follow Up of Young Women in Costa Rica Who Received Vaccine for Human Papillomavirus Types 16 and 18 and Unvaccinated Controls
|
||
Active, not recruiting |
NCT04272034 -
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05787535 -
HRYZ-T101 TCR-T Cell for HPV-18 Positive Advanced Solid Tumor
|
Phase 1 | |
Active, not recruiting |
NCT04505553 -
Oral Cryotherapy Plus Acupressure and Acupuncture Versus Oral Cryotherapy for Decreasing Chemotherapy-Induced Peripheral Neuropathy From Oxaliplatin-Based Chemotherapy in Patients With Gastrointestinal Cancer
|
Phase 2 | |
Active, not recruiting |
NCT04230759 -
Radiochemotherapy +/- Durvalumab for Locally-advanced Anal Carcinoma. A Multicenter, Randomized, Phase II Trial of the German Anal Cancer Study Group
|
Phase 2 | |
Active, not recruiting |
NCT04713618 -
Changes in Pelvic Health, Sexual Function, and Quality of Life in Women With Pelvic Cancer Undergoing Radiation Therapy
|
||
Recruiting |
NCT05438836 -
Re-optimization Based Online Adaptive Radiotherapy of Anal Cancer
|
||
Completed |
NCT00423254 -
Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer.
|
Phase 1 | |
Recruiting |
NCT02369939 -
Effects of Deep Regional Hyperthermia in Patients With Anal Carcinoma Treated by Standard Radiochemotherapy
|
Phase 3 | |
Recruiting |
NCT02628067 -
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)
|
Phase 2 | |
Recruiting |
NCT03241680 -
Study of Anal Cytologies in Patients With High Grade Cervical Intraepithelial Neoplasia (CIN II and III)
|
N/A | |
Active, not recruiting |
NCT02816879 -
Anal Cytology Collection Procedures in Predicting High-Grade Anal Dysplasia in Men Who Have Sex With Men
|
N/A | |
Recruiting |
NCT04802876 -
Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients With PD1-high mRNA Expressing Tumors
|
Phase 2 | |
Completed |
NCT03469596 -
Evaluation by MRI of Anal Canal Cell Carcinoma: is There Predictive Factor?
|